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Abstract.
Background: Centenarian studies are important sources for understanding of factors that contribute to longevity and healthy
aging. Clinico-neuropathological finding is a key in identifying pathology and factors contributing to age-related cognitive
decline and dementia in the oldest old.
Objective: To characterize the cross-sectional relationship between neuropathologies and measures of premortem cognitive
performance in centenarians.
Methods: Data were acquired from 49 centenarians (≥98 years) from the Georgia Centenarian Study. Cognitive assessment
from the time point closest to mortality was used (<1 year for all subjects) and scores for cognitive domains were established.
Neuropathologies [cerebral atrophy, ventricular dilation, atherosclerosis, cerebral amyloid angiopathy (CAA), Lewy bodies,
hippocampal sclerosis (HS), hippocampal TDP-43 proteinopathy, neuritic plaque (NP) and neurofibrillary tangle (NFT)
counts, Braak staging, and National Institute on Aging-Reagan Institute (NIARI) criteria for the neuropathological diagnosis
of Alzheimer’s disease (AD)] were compared among subjects with different ratings of dementia. Linear regression was
applied to evaluate the association between cognitive domain scores and neuropathologies.
Results: Wide ranges of AD-type neuropathological changes were observed in both non-demented and demented subjects.
Neocortical NFT and Braak staging were related to clinical dementia rating. Neocortical NFT and NP, Braak and NIARI
staging, cerebral and ventricular atrophy, HS, CAA, and TDP-43 proteinopathy were differentially associated with poor
performance in multiple cognitive domains and activities of daily living.
Conclusion: AD-type pathology was associated with severe dementia and poor cognition but was not the only variable that
explained cognitive impairment, indicating the complexity and heterogeneity of pathophysiology of dementia in the oldest old.
Keywords: Alzheimer’s disease, amyloid plaques, centenarians, cognition, neurofibrillary tangles, neuropathology
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INTRODUCTION
Centenarians are a unique demographic and are
the fastest-growing age group in many developed
nations. The number of centenarians is predicted to
reach 25 million worldwide by 2100 [1]. Centenarian
studies are important sources for our understanding
of genetics and modifiable factors that contribute to
longevity and healthy aging [2]. Because advanced
age is the number one risk factor of late-onset
Alzheimer’s disease (AD), the most common form
of dementia, it was originally assumed that dementia
is a natural process of aging [3]. However, studies in
the oldest old (≥90 years old) have shown that cog-
nitive status varied drastically from person to person
toward the end of life, implying that dementia is not
an inevitable symptom even in those living beyond
the expected human lifespan [4, 5]. Given that the
world population is shifting toward older ages, and
currently there is no treatment for AD and other forms
of dementia, there is an urgency to identify charac-
teristics associated with lower risk of dementia and
its pathology.
Appreciation in cognitive findings from cente-
narian studies have been increasing in recent years
[2]. Prevalence and incidence of dementia and age-
related cognitive impairment have been extensively
described in many centenarian studies worldwide
[5]. On the other hand, our current understanding of
clinico-pathological (CP) correlation with dementia
in centenarians is extremely limited. Existing evi-
dences suggest distinctive CP pattern from those
of less advanced age [6, 7]. Neuritic plaque (NP)
and neurofibrillary tangle (NFT) are two classical
neuropathological hallmarks of AD [8]. NP, also
known as senile plaque, is an extracellular aggrega-
tion of amyloid- (A) peptide that forms a dense
core surrounded by degenerative neurites. NFT is an
intracellular aggregate of hyperphosphorylated tau
protein. Existing neuropathological studies in the old-
est old often performed only a crude assessment
of premortem cognitive status [9–15]. The Georgia
Centenarian Study (GCS), the longest-running cen-
tenarian study in the US, offers a unique dataset that
encompasses extensive premortem neuropsycholog-
ical and postmortem neuropathological assessments
in centenarians with varied degree of cognitive sta-
tus, as well as variables that may confound the CP
association (such as gender, race, education, and
chronic illness) [16]. Prevalence of dementia, cogni-
tive functioning, and neuropathological assessment in
the GCS centenarians have been separately described
[17–19]. This report is the first comprehensive CP
characterization in the GCS.
The main objective for this present analysis was to
characterize the cross-sectional relationship between
neuropathological variables and both subjective and
objective measures of premortem cognitive perfor-
mance in centenarians from the GCS. Previous CP
studies often combined centenarians with younger
old adults (<90 years old), but findings from these
studies raised questions regarding the confounding
effect from longevity-associated characteristics of the
oldest old [20–23]. There have been limited reports on
CP correlations exclusively in 40 centenarians from
the 100-Plus Study of Dutch centenarians who were
all cognitively intact at the enrollment [24], 14 cen-
tenarians from the New England Centenarian Study
(NECS) [25], and others with very limited numbers
of subjects [9–11, 26–28]. Findings from the GCS
will expand our understanding of CP correlation as
it is one of the keys to identify pathology and factors
contributing to the prevention or delay of age-related
cognitive decline and, distinctively in centenarians,
successful aging.
METHODS
Subject recruitment
Forty-nine subjects included in this study were a
subset of centenarians (defined as ≥98 years old)
enrolled in the GCS. The protocol of the GCS has
been described in detail [16, 29]. Briefly, phase III of
the GCS was a population-based multidisciplinary
study conducted in 44 counties in northern Geor-
gia between 2001 and 2007. The aim of the GCS
is to identify biological, psychological, and social
factors contributing to survivorship and successful
aging. All protocols were performed with an approval
from the University of Georgia Institutional Review
Board. Separate approval for using de-identified data
for the present analyses was obtained from the Tufts
University/Tufts Medical Center Institutional Review
Board.
Cognitive assessment and cognitive domain
composite scoring
Cognitive assessment was performed at baseline
and every 6 months until mortality after the enroll-
ment at subject’s residence as previously described
[29]. Only subjects who had cognitive assessment
within 1 year of mortality were used for these
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analyses. Dementia status was assessed by geriatric
psychiatrists using Global Deterioration Scale (GDS)
and subjects were grouped based on GDS score. A
score of 1-2 on GDS were clinically defined as no
dementia; a score of 3 represented mild cognitive
impairment; and a score of 4–7 represented increas-
ing severity of dementia from mild to severe [30].
Objective measures of cognition were performed
using different cognitive tests previously described
[18, 31]. Cognitive tests included Mini-Mental State
Examination (MMSE), Severe Impairment Battery
(SIB), Fuld Object Memory Evaluation (FOME),
Controlled Oral Word Association Test (COWAT),
Wechsler Adult Intelligence Scale Third Edition
(WAIS-III) Similarities, Behavioral Dyscontrol Scale
(BDS), and the Consortium to Establish a Reg-
istry for Alzheimer’s Disease (CERAD) battery
which included Verbal Fluency (VF), Boston Nam-
ing Test (BNT), Constructional Praxis (CP), and
Word List Memory Test (WLMT). Depression was
assessed using Geriatric Depression Scale Short
Form (GDSSF), and activities of daily living were
assessed using Direct Assessment of Function Sta-
tus (DAFS). Scores from each test were normalized
using z-scoring among all subjects. Adapted from
Bowman et al. [32], composite scores for five cogni-
tive domains (memory, executive function, language,
visuospatial function, attention/encoding), depres-
sion, and activities of daily living were calculated
by averaging the z-scores of cognitive tests (Sup-
plementary Table 1). Global cognition composite
scores were also derived by combining total cog-
nitive testing z-scores. Only cognitive tests from
the time point closest to death were used to cal-
culate cognitive domain composite scores. Missing
test scores were excluded, and the denominator
changed accordingly for the calculation of composite
scores.
Brain collection and assessment for
neuropathology
Brain tissues were collected at autopsy at the
University of Georgia-Athens and delivered to the
University of Kentucky Alzheimer’s Disease Cen-
ter (UK-ADC) for neuropathological assessment
as previously described [19]. Assessment of neu-
ropathology included cerebral atrophy, ventricular
dilation, cerebral atherosclerosis, cerebral amyloid
angiopathy (CAA), Lewy body pathology (LBP),
hippocampal TAR DNA binding protein 43 (TDP-
43) pathology, hippocampal sclerosis (HS), infarcts,
averaged NP and NFT counts, Braak and Braak
staging (hereafter referred to as Braak staging),
and National Institute on Aging-Reagan Institute
(NIARI) criteria for the neuropathological diagno-
sis of AD. Cerebral atrophy and ventricular dilation
are measures of neuronal loss [33]. Cerebral atro-
phy was graded from absent, mild, moderate, to
severe. Ventricular dilation was assessed as absent
or present. Cerebral atherosclerosis and CAA, which
is a deposition of A in the wall of blood vessels,
are markers of cerebrovascular disease [8]. Cere-
bral atherosclerosis and CAA were graded from
absent, mild, moderate, to severe. LBP were evalu-
ated according to the consensus-based evaluation [34,
35]. Aberrant TDP-43 immunohistochemistry refers
to staining that is cytoplasmic, neuritic, or tangle like
(TDP-43 is normally localized to the nucleus). Sever-
ity of hippocampal TDP-43 pathology was graded
semi-quantitatively from absent, mild, moderate, and
severe as previously described [36]. The neuropatho-
logical criterion for HS was selective neuronal loss
and gliosis of hippocampus (Hip) section CA1 and
subiculum (Sub), not readily ascribable to another
pathology such as NFT or localizable infarction [37].
As previously described [19], NP and NFT counts
were averaged from five microscopic fields that were
most severely affected in each section from the fol-
lowing brain regions: frontal cortex (FC, Brodmann
Area 9), temporal cortex (TC, Brodmann Areas 21-
22), parietal cortex (PC, Brodmann Areas 39-40),
amygdala (Amy), entorhinal cortex (Ent), Hip sec-
tion CA1, and Sub. Braak staging was employed as a
global assessment of NFT progression as previously
described [38]: Braak staging I-II (transentorhinal);
Braak staging III-IV (limbic); Braak staging V-VI
(neocortical). Braak staging I-II is characterized by a
mild to moderate development of NFT and neuropil
thread (NT) in the transentorhinal region. A modest
number of NFT may be observed in the Hip sec-
tion CA1. Isolated NFT may be scarcely observed
in isocortical association areas including FC and TC.
In Braak staging III-IV, both transentorhinal and Ent
are severely affected by NFT and NT. Hippocampal
CA1 also contains numerous NFT, as well as limbic
structures (Amy, putamen, nucleus accumbens, thala-
mus). The Sub and isocortices in Braak staging III-IV
remain only mildly affected by NFT. In Braak stag-
ing V-VI, transentorhinal, Ent, Hip, Sub, subcortical
nuclei and isocortical cortices are severely affected
by NFT or NT. NIARI AD neuropathology criteria
summarize histological assessments of A deposits,
staging of NFT (Braak staging), and scoring of NP
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into “no”, “low”, “intermediate”, or “high” likelihood
of AD [39].
Statistical analysis
Comparisons of subject characteristics and neu-
ropathology among the four GDS groups were
performed using Kruskal-Wallis rank sum test for
continuous variables and Fisher exact test for cate-
gorical variables. Pairwise comparisons were further
performed with Wilcoxon rank sum test. An asso-
ciation between neuropathological variables and
cognitive domain scores was assessed using multiple
linear regression adjusted for gender, race, educa-
tion, hypertension, and diabetes. NP and NFT counts
were log transformed in the regression models. p val-
ues were additionally adjusted using Benjamini &
Hochberg’s false discovery rate (FDR) for multiple
comparisons (R package ‘stats’). All statistical anal-
yses were performed in R 3.3.3. Significance level
was set at = 0.05 and FDR was reported.
RESULTS
Subject characteristics
Characteristics for 49 subjects analyzed in the
present study are shown in Table 1. All subjects were
≥98 years old with an average of 102.2 years at death
(8 cases were 98 or 99 years old at death). Most
were females (90%) and Caucasians (88%). Forty-
five percent of subjects did not finish high school. On
average, each subject took 7.9 medications, including
antidepressant (29%), antipsychotic (8%), and anti-
inflammatory medications (10%). Sixteen percent
had diabetes while 51% had hypertension at death.
Among those whose data for history of smoking
and alcohol use were available (67%, most missing
Table 1
Subject Characteristics
Characteristics All subjects GDS 1-2 GDS 3 GDS 4-5 GDS 6-7 p1
(n = 49) (n = 12) (n = 10) (n = 15) (n = 12)
Age in years, mean (SD) 102.2 (2.5) 101.5 (2.0) 102.6 (2.1) 102.7 (3.3) 101.8 (2.5) 0.583
Female, n (%) 44 (90%) 9 (75%) 9 (90%) 14 (93%) 12 (100%) 0.251
Race, n (%) 0.046
Caucasian 43 (88%) 12 (100%) 10 (100%) 13 (87%) 8 (67%)
African American 6 (12%) 0 (0%) 0 (0%) 2 (13%) 4 (33%)
BMI in kg/m2, mean (SD)2 22.0 (4.4) 23.5 (4.0) 22.8 (3.3) 21.3 (4.8) 20.9 (4.9) 0.257
Education, n (%) 0.332
<High school 22 (48%) 4 (33%) 4 (40%) 7 (50%) 7 (70%)
High school 12 (26%) 4 (33%) 3 (30%) 2 (14%) 3 (30%)
>High school 12 (26%) 4 (33%) 3 (30%) 5 (36%) 0 (0%)
No data 3 0 0 1 2
Number of medications, mean (SD) 7.9 (3.7) 6.8 (3.3) 7.3 (5.3) 8.1 (2.2) 9.2 (4.1) 0.517
Antidepressant use, n (%) 14 (29%) 2 (17%) 2 (20%) 5 (33%) 5 (42%) 0.511
Antipsychotic use, n (%) 4 (8%) 0 (0%) 1 (10%) 2 (13%) 1 (8%) 0.827
Anti-inflammatory medication use, n (%) 5 (10%) 1 (8%) 3 (30%) 0 (0%) 1 (8%) 0.100
Diabetes, n (%) 8 (16%) 2 (17%) 0 (0%) 3 (20%) 3 (25%) 0.456
Hypertension, n (%) 25 (51%) 8 (67%) 3 (30%) 7 (47%) 7 (58%) 0.371
Smoking, n (%) 0.712
Never 28 (85%) 9 (82%) 8 (89%) 7 (88%) 4 (80%)
Past 4 (12%) 2 (18%) 1 (11%) 0 (0%) 1 (20%)
Present 1 (3%) 0 (0%) 0 (0%) 1 (12%) 0 (0%)
No data 16 1 1 7 7
Alcohol use, n (%) 0.145
Never 21 (64%) 4 (36%) 5 (56%) 7 (88%) 5 (100%)
Past 5 (15%) 4 (36%) 1 (11%) 0 (0%) 0 (0%)
Present 7 (21%) 3 (27%) 3 (33%) 1 (12%) 0 (0%)
No data 16 1 1 7 7
APOE 4 allele frequency3 0.09 0.04 0.10 0.12 0.11 0.167
1Kruskal-Wallis test (continuous variables) and Fisher’s exact test (categorical variables) was performed for comparisons
among four groups. Comparisons for education, smoking, and alcohol were performed only with subjects whose data were
available. 2One subject was a double amputee and BMI could not be calculated. 3The 2 or 4 allele frequency is the
ratio of number of 2 or 4 allele to the total number of alleles (two per person) in each group. APOE genotype was not
available in five subjects, two of whom had GDS 4-5 and three of whom had GDS 6-7.
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data were from demented subjects), most had no his-
tory of cigarette smoking or alcohol use. APOE 4
allele frequency was not significantly different among
GDS groups. Subject characteristics were similar
across GDS groups except the proportion of African
Americans was significantly higher in advanced GDS
groups.
The time interval between the cognitive assessment
at the time point closest to death and the autopsy
was less than one year for all subjects with a mean
of 153 ± 91 days for those whose data could be
accurately calculated (84%). Availability of cognitive
assessment data for each GDS classification is shown
in Supplementary Table 2. As expected, MMSE and
cognitive domain composite scores were significantly
different among GDS groups as described in Supple-
mentary Table 3. Composite scores were also highly
correlated among cognitive domains as shown in Sup-
plementary Table 4. None of the subjects reported a
history of clinical stroke.
Neuropathology and dementia rating
The neuropathology among centenarians is
described in Table 2. Most subjects were absent of or
had mild cerebral atrophy and ventricular dilation. All
subjects who had moderate or severe cerebral atrophy
scored ≥4 on the GDS (presence of clinical demen-
tia). Seven subjects with presence of ventricular dila-
tion had some degree of cerebral atrophy and demen-
tia. A trend between the presence of ventricular dila-
tion and dementia status was observed (p = 0.065). All
subjects had a certain degree of cerebral atheroscle-
rosis. Forty-one percent were absent of amyloid
angiopathy. Nine subjects (21%) had LBP in at least
one part of the brain—varying from the brain stem (3
subjects), limbic system (7 subjects), to neocortex (2
subjects). Certain degree of HS was present in at least
one hemisphere in five subjects (11%) not readily
ascribable to another pathology in Hip. HS impeded
the assessment of NP and NFT in Hip and Sub in
three subjects. Proteinopathy of hippocampal TDP-
43 was also observed in 8 subjects (32%) with its
severity ranging from mild (20%), moderate (10%),
to severe (2%). Although HS and hippocampal TDP-
43 proteinopathy were not significantly associated
with rating of dementia, it is worth pointing out that
all subjects who were cognitively intact (GDS 1-2)
were absent of these pathologies in Hip. Fifty-six per-
cent of subjects whose data were available (24 out of
43 subjects) had at least one small infarct, but all were
absent of medium to large infarcts.
Given the progression of NP and NFT across
different AD stages [34,36], NP counts in higher
brain structures (FC, TC, PC) and Amy were signif-
icantly greater than Ent, Hip, and Sub as expected
in this cohort of subjects with varied degrees of
cognition (p < 0.001 for all pair-wise comparisons).
Meanwhile, NFT in Amy, Ent, Hip, and Sub was
significantly higher than that in FC, TC, and PC
(p < 0.001 for all pair-wise comparisons). Medians
for NP and NFT counts were consistently lower than
means in all brain regions, describing the high fre-
quencies of subjects with NP and NFT counts lower
than mean values (Figs. 1 and 2). It is also worth
noting the comparable ranges of NP and NFT counts
across GDS groups in many brain regions. NP counts
were similar across GDS groups for all brain regions.
In contrast, NFT counts in FC, TC, and Sub in GDS
6-7 were significantly higher than those in lower GDS
groups (p < 0.05). Averaged NFT counts in PC in
GDS 6-7 were also significantly higher than those
in GDS 1-2 and GDS 3 (p < 0.05). All subjects had
some degree of NFT pathology, therefore none was
in Braak staging 0 (no NFT pathology). A signifi-
cantly higher proportion of subjects in Braak staging
V-VI was also observed in advanced GDS groups
(p < 0.05). Proportions of subjects in different NIARI
AD neuropathology criteria were not statistically sig-
nificant across GDS groups.
Neuropathology and cognitive testing
performance
The associations between neuropathological vari-
ables and composite scores of global cognition,
memory, executive function, visuospatial function,
attention/encoding, depression, and activities of daily
living, after adjusting for covariates—gender, race,
education, hypertension, and diabetes are shown in
Table 3. Variance explained for a composite score
in each linear regression model (adjusted R2) is
reported in Supplementary Table 5. Compared to
those absent of cerebral atrophy, subjects with moder-
ate or severe cerebral atrophy consistently performed
worse in global cognition (p < 0.01, FDR < 0.05 for
moderate; p < 0.05, FDR < 0.05 for severe), mem-
ory (p < 0.01, FDR < 0.05 for moderate; p < 0.05,
FDR < 0.05 for severe), executive function (p < 0.01,
FDR < 0.05 for moderate; p < 0.05, FDR < 0.10 for
severe), language (p < 0.01, FDR < 0.05 for moder-
ate), visuospatial function (p < 0.05, FDR < 0.05 for
moderate), and activities of daily living (p < 0.05,
FDR < 0.05 for moderate and severe). Mild cerebral
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Table 2
Description of neuropathology1
Neuropathology All subjects GDS 1-2 GDS 3 GDS 4-5 GDS 6-7 p2
(n = 49) (n = 12) (n = 10) (n = 15) (n = 12)
Cerebral atrophy, n (%) 0.229
Absent 17 (35%) 7 (58%) 5 (50%) 3 (20%) 2 (17%)
Mild 25 (51%) 5 (42%) 5 (50%) 9 (60%) 6 (50%)
Moderate 4 (8%) 0 (0%) 0 (0%) 2 (13%) 2 (17%)
Severe 3 (6%) 0 (0%) 0 (0%) 1 (7%) 2 (17%)
Ventricular dilation, n (%) 0.065
Absent 42 (86%) 12 (100%) 10 (100%) 11 (73%) 9 (75%)
Present 7 (14%) 0 (0%) 0 (0%) 4 (27%) 3 (25%)
Cerebral atherosclerosis, n (%) 0.236
Mild 28 (57%) 9 (75%) 6 (60%) 9 (60%) 4 (33%)
Moderate 19 (39%) 2 (17%) 4 (40%) 6 (40%) 7 (58%)
Severe 2 (4%) 1 (8%) 0 (0%) 0 (0%) 1 (8%)
Amyloid angiopathy, n (%) 0.472
Absent 20 (41%) 8 (67%) 2 (20%) 4 (27%) 6 (50%)
Mild 17 (35%) 3 (25%) 5 (50%) 6 (40%) 3 (25%)
Moderate 6 (12%) 0 (0%) 1 (10%) 3 (20%) 2 (17%)
Severe 6 (12%) 1 (8%) 2 (20%) 2 (13%) 1 (8%)
Lewy body, n (%) 0.726
Absent 34 (79%) 8 (80%) 7 (88%) 11 (85%) 8 (67%)
Present 9 (21%) 2 (20%) 1 (12%) 2 (15%) 4 (33%)
No data 6 2 2 2 0
Hippocampal TDP-43, n (%) 0.105
Absent 28 (68%) 9 (100%) 6 (75%) 8 (53%) 5 (56%)
Mild 8 (20%) 0 (0%) 1 (13%) 6 (40%) 1 (11%)
Moderate 4 (10%) 0 (0%) 1 (13%) 1 (7%) 2 (22%)
Severe 1 (2%) 0 (0%) 0 (0%) 0 (0%) 1 (11%)
No data 8 3 2 0 3
Hippocampal sclerosis, n (%) 0.363
Absent 42 (89%) 10 (100%) 9 (90%) 14 (93%) 9 (75%)
Present (unilateral or bilateral) 5 (11%) 0 (0%) 1 (10%) 1 (7%) 3 (25%)
No data 2 2 0 0 0
Small infarct, n (%) 0.253
Absent 19 (44%) 5 (50%) 1 (13%) 7 (54%) 6 (50%)
Present 24 (56%) 5 (50%) 7 (87%) 6 (46%) 6 (50%)
No data 6 2 2 2 0
Neuritic plaque, med (IQR)
Frontal cortex 6.6 (1.6–11.6) 4.2 (0.0–8.9) 6.2 (0.0–10.9) 6.6 (3.6–8.9) 10.0 (2.9–15.5) 0.390
Temporal cortex 6.4 (1.6–11.0) 6.0 (0.0–11.0) 5.4 (0.4–8.6) 6.4 (2.4–7.4) 9.9 (5.7–13.9) 0.396
Parietal cortex 6.8 (1.4–12.2) 3.0 (0.0–8.9) 4.4 (0.0–8.7) 7.4 (4.3–12.3) 10.8 (5.5–17.3) 0.119
Amygdala 4.2 (0.4–8.0) 3.9 (0.0–5.1) 4.3 (0.6–8.1) 2.8 (1.1–8.2) 6.7 (3.2–8.8) 0.400
Entorhinal cortex 0.6 (0.0–1.2) 0.1 (0.0–0.7) 0.8 (0.2–1.2) 0.8 (0.1–1.4) 0.6 (0.0–1.1) 0.340
Hippocampus3 0.0 (0.0–0.7) 0.0 (0.0–0.0) 0.0 (0.0–0.7) 0.0 (0.0–1.3) 0.0 (0.0–1.1) 0.581
Subiculum3 0.6 (0.0–1.6) 0.0 (0.0–0.6) 0.8 (0.6–1.6) 0.8 (0.0–2.1) 0.6 (0.0–1.0) 0.380
Neurofibrillary tangle, med (IQR)
Frontal cortex 0.2 (0.0–1.8) 0.0 (0.0–1.1)a 0.0 (0.0–0.4)a 0.2 (0.0–1.3)a 5.0 (0.8–9.2)b 0.011
Temporal cortex 0.6 (0.0–3.4) 0.2 (0.0–0.5)a 0.5 (0.0–1.5)a 0.2 (0.0–5.0)a 5.1 (1.5–18.9)b 0.031
Parietal cortex 0.4 (0.0–2.6) 0.0 (0.0–0.6)a 0.0 (0.0–0.3)a 0.6 (0.0–2.7)a,b 2.5 (0.4–6.5)b 0.018
Amygdala 9.2 (2.4–27.8) 3.1 (1.6–11.0) 9.8 (3.8–24.6) 8.0 (1.5–22.7) 23.9 (10.6–40.5) 0.062
Entorhinal cortex 20.0 (5.8–37.0) 22.5 (5.1–37.2) 20.1 (14.1–32.1) 7.6 (3.4–19.5) 37.4 (19.7–47.7) 0.054
Hippocampus3 10.5 (2.8–17.7) 8.2 (2.7–16.4) 13.4 (4.2–17.0) 4.4 (1.4–16.4) 17.4 (9.9–28.9) 0.234
Subiculum3 22.7 (5.0–52.7) 11.2 (4.6–19.6)a 37.2 (9.8–57.0)a,b 18.7 (3.1–27.4)a 53.2 (34.0–99.5)b 0.032
Braak staging, n (%) 0.036
I-II (transentorhinal) 17 (37%) 7 (58%) 2 (22%) 7 (47%) 1 (9%)
III-IV (limbic) 15 (33%) 3 (25%) 6 (67%) 2 (13%) 4 (36%)
V-VI (isocortical) 14 (30%) 2 (17%) 1 (11%) 5 (33%) 6 (55%)
No data3 3 0 1 1 1
NIARI AD criterion, n (%) 0.202
No AD 7 (15%) 3 (25%) 2 (20%) 1 (8%) 1 (9%)
Low likelihood 14 (30%) 5 (42%) 2 (20%) 6 (46%) 1 (9%)
Intermediate likelihood 12 (26%) 2 (17%) 5 (50%) 2 (15%) 3 (27%)
High likelihood 13 (28%) 2 (17%) 1 (10%) 4 (31%) 6 (55%)
No data 3 0 0 2 1
1Means and medians that do not share the same superscription are statistically different with pairwise comparison using Wilcoxon’s rank
sum test. 2Kruskal-Wallis test (continuous variables) and Fisher’s exact test (categorical variables) was performed for comparisons among
four groups. 3Neuritic plaques and neurofibrillary tangles in hippocampus and subiculum, including Braak staging, from three individuals
(each from GDS 3, 4-5, 6-7) could not be reliably quantified/assessed due to severe hippocampal sclerosis. GDS, Global Deterioration Scale;
IQR, Interquartile range; NIARI, National Institute on Aging-Reagan Institute; AD, Alzheimer’s disease.
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Fig. 1. Neuritic plaque (NP) counts in different regions of the brain. Global Deterioration Scale (GDS) 1-2: n = 12, GDS 3: n = 10, GDS 4-5:
n = 15, GDS 6-7: n = 12.
Fig. 2. Neurofibrillary tangle (NFT) counts in different regions of the brain. Global Deterioration Scale (GDS) 1-2: n = 12, GDS 3: n = 10,
GDS 4-5: n = 15, GDS 6-7: n = 12.
atrophy was also related to significantly lower scores
in memory, language, and activities of daily living
(p < 0.05, FDR < 0.15 for all). Presence of ventricu-
lar dilation was significantly associated with lower
scores in global cognition, executive function, and
activities of daily living (p < 0.05, FDR < 0.10 for
all). No association between cerebral atherosclero-
sis or LBP and any cognitive domain was observed.
Lower scores in global cognition, memory, exec-
utive function, and activities of daily living were
observed in moderate CAA compared to those absent
of CAA (p < 0.05, FDR < 0.10 for all). Similarly,
lower performance in memory, visuospatial function,
and attention/encoding was associated with presence
of aberrant hippocampal TDP-43 or HS (p < 0.05,
FDR < 0.10 for TDP-43; p < 0.05, FDR < 0.20 for
HS), especially severe hippocampal TDP-43 and
visuospatial function (p < 0.01, FDR < 0.05). How-
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ever, this association was established upon one
subject who had severe hippocampal TDP-43 pro-
teinopathy.
Higher NP counts in FC was associated with lower
visuospatial function score (p < 0.05, FDR > 0.20),
and higher NP counts in TC was associated
with lower global cognition and visuospatial
function scores (p < 0.05, FDR < 0.15 for both;
Table 3). On the contrary, higher NP counts in
PC were consistently related to worse perfor-
mance in global cognition (p < 0.05, FDR < 0.05),
memory (p < 0.05, FDR < 0.05), executive func-
tion (p < 0.05, FDR < 0.10), visuospatial function
(p < 0.01, FDR < 0.05). NP counts in Amy, Ent, Hip,
and Sub were not statistically related to any cognitive
domain, depression, or activities of daily living.
Compared to NP, associations between NFT counts
and cognitive performance were more consistently
observed. Averaged NFT counts in FC, TC, and
PC were negatively associated with global cognition
(p < 0.01, FDR < 0.01 for TC; p < 0.001, FDR < 0.01
for FC, PC), memory (p < 0.01, FDR < 0.01 for FC;
p < 0.01, FDR < 0.05 for TC, PC), language (p < 0.05,
FDR < 0.05 for FC, TC; p < 0.01, FDR < 0.05 for
PC), visuospatial function (p < 0.05, FDR < 0.10
for FC; p < 0.01, FDR < 0.05 for TC; p < 0.01,
FDR < 0.01 PC), and activities of daily living
(p < 0.01, FDR < 0.05 for FC, TC, PC). NFT counts
in PC was significantly associated with atten-
tion/encoding score (p < 0.01, FDR < 0.05). NFT
counts in TC were also negatively associated with
executive function (p < 0.05, FDR < 0.10). Signif-
icant associations between higher NFT counts in
Sub and lower scores in global cognition (p < 0.01,
FDR < 0.05), memory (p < 0.01, FDR < 0.05), lan-
guage (p < 0.05, FDR < 0.10), and activities of daily
living (p < 0.05, FDR < 0.10) were observed. NFT
counts in Hip were also significantly associated with
executive function (p < 0.05, FDR > 0.20), as well
as NFT counts in Amy and Ent with visuospatial
function (p < 0.05, FDR < 0.15 for Amy; p < 0.05,
FDR > 0.20 for Ent).
Advanced Braak staging (Braak staging V-VI) and
NIARI AD criteria (high likelihood of AD) were
both significantly associated with poor performance
in global cognition (p < 0.05, FDR < 0.05 for Braak
staging; p < 0.01, FDR < 0.05 for NIARI AD criteria)
and memory (p < 0.01, FDR < 0.05 for Braak stag-
ing; p < 0.05, FDR < 0.05 for NIARI AD criteria).
Advanced Braak stage was also significantly related
to lower score in language (p < 0.05, FDR < 0.10), and
both advanced Braak stage and NIARI AD criteria
were related to lower score in visuospatial function
(p < 0.05, FDR < 0.10 for both). Depression was not
significantly associated with any neuropathological
variables measured in this present study.
DISCUSSION
AD-type pathology in non-demented and
demented centenarians
Neuropathological changes have been previously
described in centenarians pooled from three differ-
ent cohorts including the GCS [16], the Nun Study
[20, 21], and the UK-ADC [41], and its primary find-
ing demonstrated that AD-type lesion (NP, NFT) was
not universal in the oldest old [19]. In this current
CP assessment in the GCS cohort, we observed that
distributions of neuropathology were similar among
centenarians who were rated by geriatric psychia-
trists as having intact cognition, MCI, mild and severe
dementia, with an exception of advanced NFT pro-
gression in the neocortex (FC, TC, PC) and Sub.
For example, 45% of non-demented subjects had
intermediate or high likelihood of AD according to
the NIARI AD neuropathology criteria, which con-
firmed the finding from the 90 + Study where the
proportion was 49% [42]. There were two decedents
categorized as high likelihood of AD and Braak stag-
ing V, but both had normal cognition (GDS 1-2).
Both subjects were Caucasian, high school gradu-
ates, and community-based dwellers, all of which
were characteristics associated with better ratings of
cognitive function in the GCS [17]. Our observa-
tions underline the heterogeneity of neuropathology
and the possibility of living beyond 100 years with-
out clinical manifestation of cognitive decline or
dementia under certain degrees of neuropathologi-
cal changes [5]. In line with our findings, an analysis
in postmortem brains from 40 centenarians from the
100-Plus Study whose premortem MMSE score were
23.7 ± 4.6 (MMSE score: 24–30 = normal cognition;
19–23 = mild; 10–18 = moderate; or ≤9 = severe cog-
nitive impairment) also demonstrated a wide range of
AD-type pathology, but none had Braak staging V-VI
[24, 43]. Two out of six non-demented centenarians
from the NECS also had significant AD neuropatho-
logical changes, but Braak staging was also limited to
≤IV [25]. In younger old adults, AD-type lesions may
be present during preclinical AD stages without any
signs of dementia unless severe neocortical AD-type
lesions are observed [44–46]. Although rare, there
were also reports on Braak staging V-VI subjects
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Table 3
Linear regression  coefficients (standard error) demonstrating the relationship between neuropathological variables and composite scores of six cognitive domains, depression, and activities of
daily living adjusted for sex, race, education, hypertension, and diabetes1
Neuropathology Global Memory Executive Language Visuospatial Attention/ Depression Activities of
cognition (n = 49) function (n = 49) function Encoding (n = 42) daily living
(n = 49) (n = 49) (n = 29) (n = 24) (n = 49)
Cerebral atrophy
Absent 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref)
Mild –0.43 (0.22) –0.61 (0.24)* –0.36 (0.25) –0.46 (0.22)* –0.12 (0.35) 0.77 (0.45) 0.52 (0.29) –0.63 (0.28)*
Moderate –1.28 (0.41)** –1.46 (0.44)** –1.31 (0.47)** –1.42 (0.41)** –2.27 (0.91)* 1.75 (1.49) 0.52 (0.58) –1.18 (0.53)*
Severe –1.15 (0.44)* –1.26 (0.47)* –1.12 (0.50)* –0.88 (0.44) –0.78 (0.90) –0.99 (1.01) –0.98 (0.89) –1.49 (0.56)*
Ventricular dilation
Absent 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref)
Present –0.73 (0.30)* –0.66 (0.34) –0.72 (0.34)* –0.78 (0.30)* –0.73 (0.57) –0.74 (0.78) 0.73 (0.45) –0.82 (0.38)*
Cerebral atherosclerosis
Mild 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref)
Moderate –0.15 (0.26) –0.06 (0.29) –0.08 (0.29) –0.02 (0.26) –0.17 (0.48) –0.42 (0.52) 0.07 (0.32) –0.04 (0.33)
Severe –0.45 (0.60) –0.20 (0.67) –0.19 (0.67) 0.22 (0.61) 0.11 (1.07) –1.11 (1.23) 1.20 (0.93) –0.20 (0.75)
Amyloid angiopathy
Absent 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref)
Mild 0.00 (0.25) –0.27 (0.27) 0.01 (0.26) –0.07 (0.25) –0.23 (0.38) –0.31 (0.42) –0.14 (0.32) 0.14 (0.30)
Moderate –0.74 (0.36)* –0.87 (0.40)* –1.01 (0.38)* –0.55 (0.37) –1.03 (0.73) –1.57 (1.00) –0.25 (0.49) –0.98 (0.44)*
Severe –0.17 (0.36) –0.24 (0.39) –0.11 (0.38) –0.40 (0.36) –0.09 (1.02) –1.56 (0.85) –0.24 (0.53) –0.05 (0.43)
Lewy body
Absent 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref)
Present –0.20 (0.31) –0.15 (0.33) 0.13 (0.34) –0.02 (0.31) –0.66 (0.73) –0.33 (0.88) –0.76 (0.42) –0.21 (0.36)
Hippocampal TDP-43
Absent 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref)
Mild –0.32 (0.31) –0.71 (0.32)* –0.23 (0.36) –0.35 (0.32) –1.29 (0.44)* –1.59 (0.62)* –0.05 (0.42) 0.09 (0.38)
Moderate –0.67 (0.44) –0.97 (0.46)* –0.36 (0.52) –0.46 (0.46) no data no data –0.67 (0.76) –0.73 (0.54)
Severe –1.14 (0.80) –1.25 (0.83) –0.95 (0.94) –1.00 (0.84) –2.98 (0.82)** –1.26 (1.16) 0.51 (1.01) –0.84 (0.98)
Hippocampal sclerosis
Absent 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref)
Present –0.67 (0.41) –0.88 (0.44)* –0.39 (0.47) –0.46 (0.41) –2.20 (1.02)* –1.44 (1.34) –0.24 (0.60) –0.70 (0.51)
Small infarct
Absent 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref)
Present –0.18 (0.26) –0.07 (0.28) –0.16 (0.29) –0.21 (0.25) –0.05 (0.46) 0.49 (0.53) –0.31 (0.33) –0.28 (0.30)
Neuritic plaque1
Frontal cortex –0.18 (0.10) –0.16 (0.11) –0.17 (0.11) –0.14 (0.10) –0.34 (0.15)* –0.35 (0.18) –0.06 (0.14) –0.14 (0.13)
Temporal cortex –0.20 (0.10)* –0.16 (0.11) –0.21 (0.11) –0.13 (0.10) –0.41 (0.15)* –0.37 (0.19) –0.12 (0.13) –0.19 (0.13)
Parietal cortex –0.24 (0.10)* –0.28 (0.10)* –0.22 (0.11)* –0.16 (0.10) –0.43 (0.14)** –0.35 (0.20) –0.10 (0.13) –0.19 (0.12)
Amygdala –0.14 (0.11) –0.21 (0.12) –0.19 (0.12) –0.08 (0.12) –0.30 (0.20) –0.34 (0.23) –0.08 (0.15) –0.15 (0.14)
(Continued)
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(Continued)
Neuropathology Global Memory Executive Language Visuospatial Attention/ Depression Activities of
cognition (n = 49) function (n = 49) function Encoding (n = 42) daily living
(n = 49) (n = 49) (n = 29) (n = 24) (n = 49)
Entorhinal cortex –0.28 (0.24) –0.40 –0.29 (0.26) –0.31 (0.23) –0.47 (0.41) –0.76 (0.45) 0.00 (0.32) –0.18 (0.30)
Hippocampus2 –0.05 (0.24) (0.25) –0.21 (0.26) –0.21 (0.26) 0.13 (0.24) –0.15 (0.39) 0.57 (0.50) –0.42 (0.27) –0.20 (0.29)
Subiculum2 –0.02 (0.22) –0.20 (0.24) –0.09 (0.24) 0.00 (0.22) –0.66 (0.44) –0.90 (0.68) –0.29 (0.27) –0.09 (0.27)
Neurofibrill ary tangle1
Frontal cortex –0.44 (0.12)*** –0.45 (0.14)** –0.27 (0.08) –0.31 (0.13)* –0.52 (0.25)* –0.39 (0.34) 0.13 (0.24) –0.39 (0.16)**
Temporal cortex –0.37 (0.10)** –0.37 (0.12)** –0.26 (0.13)* –0.29 (0.11)* –0.51 (0.19)** –0.35 (0.30) 0.04 (0.19) –0.36 (0.14)**
Parietal cortex –0.43 (0.12)*** –0.39 (0.13)** –0.27 (0.14) –0.34 (0.12)** –0.66 (0.18)** –0.75 (0.32)** 0.07 (0.22) –0.40 (0.15)**
Amygdala –0.17 (0.08)* –0.18 (0.09) –0.12 (0.09) –0.13 (0.08) –0.34 (0.13)* –0.18 (0.19) 0.05 (0.11) –0.20 (0.10)
Entorhinal cortex –0.10 (0.09) –0.07 (0.10) –0.01 (0.10) –0.12 (0.09) –0.41 (0.18)* –0.17 (0.25) –0.03 (0.12) –0.11 (0.11)
Hippocampus2 –0.15 (0.11) –0.25 (0.11)* –0.02 (0.12) –0.14 (0.11) –0.16 (0.17) –0.17 (0.21) –0.03 (0.13) –0.08 (0.13)
Subiculum2 –0.24 (0.09)** –0.30 (0.09) ** –0.15 (0.10) –0.20 (0.09)* –0.27 (0.15) –0.08 (0.19) –0.06 (0.12) –0.25 (0.11)*
Braak staging2
I-II (transentorhinal) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref)
III-IV (limbic) –0.16 (0.28) –0.15 (0.29) –0.06 (0.33) –0.05 (0.28) –0.39 (0.41) 0.12 (0.57) –0.27 (0.36) –0.25 (0.36)
V-VI (isocortical) –0.73 (0.28)*0 –0.91 (0.29)** –0.41 (0.33) –0.60 (0.29)* –1.07 (0.43)* –0.55 (0.70) –0.13 (0.38) –0.61 (0.36)
NIARI AD criterion
No AD .00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref) 0.00 (ref)
Low likelihood –0.22 (0.31) –0.13 (0.36) –0.32 (0.37) 0.05 (0.33) 0.46 (0.53) –0.33 (0.76) –0.75 (0.42) –0.07 (0.44)
Intermediate likelihood –0.49 (0.33) –0.41 (0.38) –0.58 (0.40) –0.17 (0.35) –0.42 (0.49) –0.87 (0.77) –0.56 (0.44) –0.45 (0.46)
High likelihood –0.95 (0.32)** –0.99 (0.37)* –0.72 (0.39) –0.66 (0.34) –1.14 (0.48)* –1.22 (0.94) –0.57 (0.46) –0.69 (0.45)
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Texts in bold: FDR < 0.05 after an adjustment for multiple comparisons across domains. 1Neuritic plaques and neurofibrillary tangles were log transformed with
log (x + 1) in the regression models. 2Neuritic plaques and neurofibrillary tangles in hippocampus and subiculum, including Braak staging, from three individuals (each from GDS 3, 4-5, 6-7)
could not be reliably quantified/assessed due to severe hippocampal sclerosis. GDS, Global Deterioration Scale; IQR: Interquartile range; NIARI, National Institute on Aging-Reagan Institute;
AD, Alzheimer’s disease.
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who appeared to be clinically non-demented across
multiple studies [46]. A case report from the Nun
Study revealed a subject who had excellent cogni-
tive performance up until death at age 85 with an
abundance of neocortical senile plaques and Braak
staging VI at postmortem examination [20]. A resis-
tance to the expression of symptoms in the face
of neuropathology has been previously described as
cognitive reserve by Stern [47], which is associated
with characteristics such as high education, intel-
ligence, socioeconomic status, and daily tasks that
are cognitively demanding. Our observations among
centenarians without dementia also supported the the-
ory of cognitive reserve widely accepted in younger
old adults, although it is still undetermined if higher
cognitive reserve prevents or merely delays the com-
mencement of age-related cognitive impairment.
We also observed a wide range of AD-type pathol-
ogy in demented centenarians. Even in cases rated as
having severe dementia (GDS 6-7) two of 12 cente-
narians were free of NFT in the neocortex and NP in
any brain region analyzed, which were likely to be
cases of other forms of dementia given both dece-
dents had cerebral atherosclerosis and infarctions,
and one also had cerebral atrophy. It is important
to point out that GDS rating does not distinguish
among types of dementia [30]. Previous analysis
demonstrated extensive concurrence of cerebrovas-
cular disease, AD, HS, and Lewy body dementia
pathologies in nonagenarian, centenarian, and super-
centenarian (≥110 years) brains [11, 19, 24, 42].
Although single neuropathological entities (except
neocortical NFT) were not associated with demen-
tia rating in the GCS (Table 2), all centenarians who
were absent of dementia (GDS 1–3) also had low
degree of neuronal loss (absent of ventricular dila-
tion and absent or low cerebral atrophy). All subjects
who were cognitively intact (GDS 1-2) were also
absent of HS and hippocampal TDP-43 proteinopa-
thy. The accumulation of concomitant pathologies
other than AD-type lesions due to extreme aging may
elicit the manifestation of dementia symptoms even
with an absence or a low degree of AD-type pathol-
ogy [48–50]. For example, the relationship between
HS and lower cognitive performance among cente-
narians from the Nun Study and the UK-ADC were
also independent of NFT and NP [36], to the extent
that Crystal et al suggested all subjects with HS
were demented [51]. Moreover, although the risk of
AD increases as age increases [3], the prevalence of
AD-type pathological diagnosis at autopsy seems to
decline in many cohorts of nonagenarians and cen-
tenarians while the prevalence of non-AD dementia
may be as high as 50% [4, 22, 25, 36, 42, 51, 52].
In the GCS, 38% of demented centenarians (GDS
4–7) were diagnosed with either absence or low like-
lihood of AD according to the NIARI criteria [39, 53].
Individuals prone to develop AD may be more likely
to die at younger ages and may explain decreased
incidence rates at advanced ages [54]. Epidemiolog-
ical and clinical studies, including ours, suggest the
pathophysiology of dementia in centenarians is com-
plex and heterogeneous due to age-related non-AD
pathological changes, less pertinent to single patho-
logical entities, and may be different from younger
old adults due to their increased resistance to biolog-
ical and psychological stress as demonstrated by the
ability to live beyond 100 years [7].
A nonlinear progression of NP and NFT during
the progression of AD has previously been reported
in younger old adults [50]. In our present study, a
sharp increase in neocortical Sub NFT (as well as a
trend in Amy and Ent) was observed in the severe
dementia cases (GDS 6-7), consistent with Braak
and Braak’s description of neuropathological staging
of AD [38]. Neocortical NFT has been consistently
associated with dementia status across other studies
in the oldest old [9, 10, 14, 24, 42, 55]. We did not
observe a significant increase in NP in neocortices
or NFT in other brain regions except Sub during ear-
lier stages of AD as observed in younger old adults
[50]. This could be explained by GDS’s inability of
distinguishing AD from non-AD cases [30]. Never-
theless, it has been proposed that the oldest old might
have a different neuropathological progression from
younger old adults [6, 7], and the strength of the
association between AD-type pathology and cogni-
tion was reported to decline with age [22, 52]. Still,
NP lesion appeared to be related to cognitive status
in some oldest old studies to a certain extent, but the
association was stronger with NFT [14, 42, 55]. We
also observed that neocortical NFT was also more
consistently related to cognitive status than NP in the
GCS. Moreover, four other studies in the oldest old
also supported our finding that NFT in Hip section
CA1 was not associated with cognitive status [9, 14,
15, 56]. This is different from the findings in younger
old adults where a quick NFT invasion of CA1 is
observed with advancing dementia [6, 7].
Neuropathology and objective test performance
Similar to GDS, which was subjectively assessed
by geriatric psychologists in the GCS, we observed
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that neocortical NFT, and to a lesser extent for NP,
was related to poor performance in multiple cogni-
tive domains and activities of daily living measured
by cognitive performance tests. Apart from our study,
only one other centenarian study, the 100-Plus Study,
reported CP correlations with different cognitive
domains [24]. In the 100-Plus Study, advanced Braak
staging, and to a much lesser extent for A pathol-
ogy, were associated with lower performance on the
MMSE, the Visual Association Test (VAT), and the
Clock Drawing Test (CDT), though these associa-
tions did not reach statistical significance. MMSE
is a measure of global cognition [57], VAT is a test
for episodic memory [58], and CDT measures visu-
ospatial and executive function [59]. Performance
on all of these cognitive domains, except executive
function, was negatively associated with neocortical
NFT load in the GCS centenarians. We also observed
that Braak staging V-VI (neocortical) and NIARI’s
“high likelihood of AD” were specifically related to
deficits in global cognition and memory but not other
cognitive domains after FDR adjustment. The CP
differences between NFT and Braak staging could
possibly be explained by a decreased sensitivity after
summarizing a continuous NFT load to an ordinal
Braak staging. Nevertheless, Gold et al suggested that
Braak staging might not be accurately predictive of
cognitive abilities in centenarians and different neu-
ropathological criteria should be considered for the
oldest-old [12].
Apart from NP and NFT, moderate and severe cere-
bral atrophy was significantly associated with poor
performance across multiple cognitive domains and
activities of daily living. Similarly, ventricular dila-
tion, also a measure of neuronal loss, had a borderline
association with dementia status (p = 0.065). How-
ever, it was questionable if neuronal loss served as
an independent predictor of cognitive status since a
correlative trend was observed between ventricular
dilation and NFT in FC, TC, PC, and Sub (p < 0.10,
Supplementary Table 6). This observation contra-
dicted previous report on the dissociation between
neuronal loss and NFT [15]. A lack of region-specific
assessment also hindered the ability to compare our
findings with other oldest-old studies. In one study,
neuronal count in Ent and Hip were not significantly
different among demented and non-demented sub-
jects [56], while significant neuronal loss in Ent,
FC, TC, but not Hip and Sub was observed among
demented subjects in a different cohort [15]. Fur-
thermore, severity of CAA was strongly associated
with worse performance on CDT (visuospatial and
executive function) in the 100-Plus Study [24]. In
the GCS, moderate CAA was associated with poor
performance in global cognition, memory, executive
function, and activities of daily living. Findings form
these two centenarian studies differed from findings
in younger old subjects where most of individuals
with CAA remained asymptomatic [60]. Similar to
CAA, the association between HS or hippocampal
TDP-43 pathology and poor cognition was not con-
sistently observed in the GCS as it was reported
previously [36], likely due to limited numbers of
severe cases or the heterogenous pathophysiology of
dementia in the oldest-old as mentioned earlier [22,
25, 51].
Study limitations
General limitations in the CP studies of AD and
dementia have been thoroughly described by Nelson
et al. [50]. Similar to other reports, NP and NFT
were analyzed quasi-linearly with regards to cog-
nitive function for the purpose of CP correlations
even though AD pathology progresses non-linearly
during different stages of the disease. Our sample
size was relatively small, especially cases of severe
pathologies, and due to high cases of missing val-
ues variables such as APOE genotype, alcohol use,
and smoking status were not controlled for. Cogni-
tive data were derived from the assessment within
one year prior to death for all subjects, but a termi-
nal drop in cognitive function within the final year
of life was previously observed in older individuals
[61]. Cognitive tests may have different sensitivity
among demented and non-demented subjects, and
their application to centenarians is scarcely explored.
Sixty-one percent of subjects, mostly those with
dementia, also did not complete the entire testing
battery (Supplementary Table 2). However, cognitive
domain z-scores could be calculated from other cog-
nitive tests with available data. Finally, limitations in
the extrapolation of findings in centenarians needed
to be highlighted. CP findings in the GCS centenari-
ans could not be directly compared with lesser-aged
cohorts since neuropathological assessment was not
performed in those who may share similar social and
biological factors relevant to neuropathological and
cognitive outcomes [31]. Longevity-associated char-
acteristics may disengage findings in centenarians
from younger populations (i.e., survivorship bias).
Nevertheless, as the world population is aging and
centenarians are the fastest-growing demographic in
developed nations [7], research findings in this unique
J. Tanprasertsuk et al. / Clinico-Neuropathologies in Centenarians 47
group of population will become more relevant to the
general population.
In summary, we have observed that neuropatholog-
ical changes, mainly presence of neocortical NFT,
and to a lesser extent (possibly due to their low
prevalence) neocortical NP, measures of neuronal
loss, CAA, HS and hippocampal TDP-43 proteinopa-
thy were associated with severe dementia and poor
performance in multiple cognitive domains in cen-
tenarians. However, AD-type pathology was not the
only variable that explained cognitive impairment,
which was also observed in other oldest old studies
[22, 52]. The wide ranges of AD-type neuropatho-
logical changes observed in non-demented subjects
supported the theory of cognitive reserve, while
wide ranges of AD-type neuropathology observed
in demented subjects supported the complexity and
heterogeneity of pathophysiology of dementia in the
oldest old. Our observations supported that CP corre-
lations in the oldest old may be different from younger
older adults and warranted further investigation of
characteristics associated with cognitive reserve and
the pathophysiology of dementia in this unique pop-
ulation.
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